Skip to main content

Advertisement

Table 1 Distribution of the analyzed parameters in the whole population

From: Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study

Parameters Total number (%)
Age  
 <60 years 788 (58.46%)
 ≥60 years 560 (41.54%)
Lenalidomide use  
 No 992 (73.59%)
 Yes 356 (26.41%)
Hematological toxicity  
 No 1260 (93.47%)
 Yes 88 (6.53%)
Baseline cytopenia  
 No 1016 (75.37%)
 Yes 332 (24.63%)
Number of parameters  
 0 402 (29.82%)
 1 630 (46.74%)
 2 252 (18.69%)
 3 54 (4.01%)
 4 10 (0.74%)
  1. Distribution of the four analyzed parameters potentially affecting PBSC collection in 1,348 newly diagnosed myeloma patients. Lenalidomide use: up to four cycles; baseline cytopenia: Hb <10 g/dl, neutrophil count <1 × 109/L, platelet count <100 × 109/L: at least one at diagnosis; hematological toxicity: grade 3 or 4 during induction therapy (CTCAE v4). PBSC, peripheral blood stem cells.